Premium
The treatment of Helicobacter pylori infection
Author(s) -
POUNDER R. E.,
WILLIAMS M. P.
Publication year - 1997
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.11.s1.9.x
Subject(s) - medicine , helicobacter pylori , urea breath test , proton pump inhibitor , gastroenterology , cancer , serology , clinical trial , lymphoma , helicobacter pylori infection , rabeprazole , helicobacter infections , intensive care medicine , immunology , antibody
Indications for eradication of Helicobacter pylori infection have widened since the National Institutes of Health consensus conference in 1994. It is argued that they should now include infected patients with non‐ulcer dyspepsia, those concerned about the risk of gastric cancer, patients with gastric lymphoma, and those requiring long‐term treatment with a proton pump inhibitor. Problems with existing clinical trials are discussed, and the results of different treatment regimens are discussed. It is proposed that future eradication trials should investigate H. pylori ‐infected subjects identified by serology, rather than ulcer patients, and that eradication is proved only by a pair of 13 C‐urea breath tests.